Patents by Inventor Stephen Liggett

Stephen Liggett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12257248
    Abstract: Disclosed herein are compounds useful for treating obstructive lung diseases. The compounds are TAS2Rs agonists and may further be used to treat disorders and conditions implicated by TAS2R. In some instances the disclosed compounds can be used to treat asthma.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: March 25, 2025
    Assignees: University of South Florida, Rutgers, The State University of New Jersey
    Inventors: Stephen Liggett, James Leahy, Donghwa Kim, Steven An
  • Publication number: 20220062274
    Abstract: Disclosed herein are compounds useful for treating obstructive lung diseases. The compounds are TAS2Rs agonists and may further be used to treat disorders and conditions implicated by TAS2R. In some instances the disclosed compounds can be used to treat asthma.
    Type: Application
    Filed: September 1, 2021
    Publication date: March 3, 2022
    Inventors: Stephen Liggett, James Leahy, Donghwa Kim, Steven An
  • Publication number: 20080096982
    Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Application
    Filed: August 13, 2007
    Publication date: April 24, 2008
    Inventors: Stephen Liggett, Michael Bristow
  • Publication number: 20060292565
    Abstract: Methods for cardiovascular disease assessment in an individual comprise detecting the presence or absence of a fragment encoding a polymorphic alpha-2C (?2C DEL322-325) adrenergic receptor in a sample from an individual; and detecting the presence or absence of a fragment encoding a polymorphic beta-1 adrenergic receptor (?1Arg389) in a sample from the individual. Methods for delaying development of cardiovascular disease in an individual, methods for delaying progression or early death associated with cardiovascular disease in an individual, methods of genetic counseling for cardiovascular disease in an individual are also provided.
    Type: Application
    Filed: September 9, 2003
    Publication date: December 28, 2006
    Inventors: Kersten Small, Stephen Liggett
  • Publication number: 20060177838
    Abstract: Abstract of the Disclosure The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).
    Type: Application
    Filed: September 14, 2005
    Publication date: August 10, 2006
    Applicants: The Regents of the University of Colorado, The University of Cincinnati
    Inventors: Stephen Liggett, Michael Bristow
  • Publication number: 20060073508
    Abstract: The present invention includes polymorphisms in nucleic acids encoding the alpha-2B, alpha-2A, and alpha-2C adrenergic receptor and expressed alpha-2B, alpha2A and alpha-2C adrenergic receptor molecule. The invention also pertains to methods and molecules for detecting such polymorphisms. The invention further pertains to the use of such molecules and methods in the diagnosis, prognosis, and treatment of diseases such as cardiovascular and central nervous system disease.
    Type: Application
    Filed: September 22, 2005
    Publication date: April 6, 2006
    Inventors: Kersten Small, Stephen Liggett
  • Publication number: 20050112632
    Abstract: Methods and compositions for the detection, diagnosis, and prevention of cardiac conditions are provided. Polymorphisms of ?1-adrenergic receptor are provided. The Gly389 ?1-adrenergic receptor variants are not as responsive to treatment ? blockers such as carvedilol, metoprolol or bisoprol. Thus, genotyping ?1-adrenergic receptor polymorphisms is useful for predicting relative responsiveness to treatment with beta blockers. The Gly389 polymorphism also may be used, alone or in conjunction with other adrenergic receptor polymorphisms, to predict relative risk of developing cardiovascular diseases such as heart failure or to predict relative survival rate in patients with heart failure or other cardiovascular diseases. Also provided are transgenic mice and transgenic cells expressing the ?1-adrenergic receptor polymorphisms, and their use in identifying therapeutic agents.
    Type: Application
    Filed: September 13, 2004
    Publication date: May 26, 2005
    Inventors: Stephen Liggett, Lynne Wagoner
  • Publication number: 20050074772
    Abstract: The present invention includes polymorphisms in nucleic acids encoding the alpha-2A adrenergic receptor and expressed alpha-2A adrenergic receptor molecule. The invention also pertains to methods and molecules for detecting such polymorphisms and transgenic animals expressing alpha-2A adrenergic receptor molecules. The invention further pertains to the use of such molecules and methods in the diagnosis, prognosis, and treatment of diseases such as cardiovascular and central nervous system diseases.
    Type: Application
    Filed: August 11, 2003
    Publication date: April 7, 2005
    Inventors: Kersten Small, Stephen Liggett
  • Patent number: 6316188
    Abstract: Methods for characterizing patients diagnosed with histaminergic diseases are described. Nucleic acid molecules that include a histamine-N-methyltransferase intron variant sequence associated with a histaminergic disease also are described.
    Type: Grant
    Filed: September 29, 1998
    Date of Patent: November 13, 2001
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Lan Yan, Stephen Liggett, Raymond E. Galinsky, Richard M. Weinshilboum, Herb M. Lachman